State of New Jersey Common Pension Fund D Trims Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

State of New Jersey Common Pension Fund D decreased its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 0.7% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 32,698 shares of the biotechnology company’s stock after selling 242 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Sarepta Therapeutics were worth $4,084,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Innealta Capital LLC purchased a new stake in Sarepta Therapeutics during the 2nd quarter valued at approximately $31,000. New Covenant Trust Company N.A. purchased a new stake in shares of Sarepta Therapeutics in the first quarter worth about $32,000. Nkcfo LLC bought a new position in Sarepta Therapeutics during the second quarter valued at approximately $43,000. Riggs Asset Managment Co. Inc. grew its holdings in Sarepta Therapeutics by 33.3% during the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 75 shares in the last quarter. Finally, UMB Bank n.a. increased its stake in Sarepta Therapeutics by 105.9% in the 3rd quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 197 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on SRPT shares. Guggenheim boosted their price target on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Jefferies Financial Group initiated coverage on shares of Sarepta Therapeutics in a report on Monday, October 21st. They issued a “buy” rating and a $165.00 price target for the company. William Blair raised Sarepta Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Raymond James reaffirmed an “outperform” rating and issued a $150.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. Finally, Piper Sandler cut their target price on Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. One research analyst has rated the stock with a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $181.33.

Insider Activity

In other Sarepta Therapeutics news, Director Michael Andrew Chambers acquired 37,038 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, August 16th. The stock was bought at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the purchase, the director now directly owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. This represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Michael Andrew Chambers acquired 37,038 shares of the business’s stock in a transaction dated Friday, August 16th. The stock was purchased at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the acquisition, the director now directly owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Stock Performance

SRPT stock opened at $114.32 on Wednesday. Sarepta Therapeutics, Inc. has a 1-year low of $76.61 and a 1-year high of $173.25. The business has a 50-day moving average price of $125.15 and a 200 day moving average price of $132.80. The company has a market capitalization of $10.92 billion, a P/E ratio of 91.46 and a beta of 0.81. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.19.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.